TRIAL DATA
Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancerThe REVERCE II trial randomized patients with RAS wild-type metastatic colorectal cancer to receive either regorafenib followed by anti-EGFR therapy or the reverse sequence, evaluating overall survival as the primary endpoint. (The Oncologist)